drugset / Trial / NCT05514106

MIBG in Aging and Neurologic Disorders

NCT05514106 ↗

Phase 4 Enrolling by invitation 50 enrolled Mayo Clinic
NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of the study is to investigate the use of a special radioactive drug called 123I-MIBG and myocardial MIBG scintigraphy. This scan may be able to help determine who may have a certain kind of neurologic disorder called Lewy Body Disease. The overall purpose of this study is to correlate myocardial MIBG scintigraphy findings with clinical diagnosis. Myocardial MIBG scintigraphy imaging will be combined with other clinical, neuropsychological and neuroimaging findings to improve the prediction for underlying Lewy Body Disease.

Timeline

Start
2023-05-08
Primary completion
2026-09
Completion
2026-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Metaiodobenzylguanidine Diagnostic / imaging agent — —